Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9762519 | 0.78 | HDAC7 (0.47) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL1897128 | 0.77 | TSHR (0.50) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL8257353 | 0.74 | CA2 (0.53) | CA2CA1MAPK1 | |
| SCHEMBL19910585 | 0.74 | CA2 (0.70) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL19135674 | 0.74 | MMP3 (0.55) | CA2CA1HDAC8HDAC6HDAC3 | |
| SCHEMBL24932772 | 0.74 | CA2 (0.70) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL2483893 | 0.74 | MMP3 (0.55) | CA2CA1HDAC8HDAC6HDAC3 | |
| SCHEMBL20987781 | 0.74 | MMP3 (0.55) | CA2CA1HDAC8HDAC6HDAC3 | |
| SCHEMBL21664527 | 0.74 | MMP3 (0.55) | CA2CA1HDAC8HDAC6HDAC3 | |
| SCHEMBL7750482 | 0.74 | CA2 (0.70) | CA2CA1HDAC8HDAC6HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450277-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | CA2 1970/4885CA1 1715/4885HDAC8 2694/4885 |
| US-20190084939-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | CA2 1970/4885CA1 1715/4885HDAC8 2694/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | CA2 4874/4885CA1 4879/4885HDAC8 1913/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | CA2 4874/4885CA1 4879/4885HDAC8 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.